SOBI (SOBI) News
Follow SOBI (SOBI) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 10 public stories across 7 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Swedish Orphan Biovitrum Returns to Profit in Q3, Updates FY26 Outlook
Swedish Orphan Biovitrum said it returned to profit in the third quarter of 2026 from a year-earlier loss, helped by higher revenue, especially in Haematology. The company also updated its annual revenue outlook.
EARNINGS | Oct 27, 2026, 08:32 AM UTC
M
Sobi Raises Full-Year 2026 Revenue Growth Guidance
Sobi officially raised its revenue growth guidance for fiscal 2026, updating its previously stated financial expectations.
EQUITY | Oct 27, 2026, 08:32 AM UTC
M
Sobi Raises 2026 Revenue Growth Outlook
EARNINGS | Oct 27, 2026, 07:31 AM UTC
L
Change in number of shares and votes in Sobi
Change in number of shares and votes in Sobi
EQUITY | Sep 30, 2026, 06:15 AM UTC
L
Sobi to present clinical data on Gamifant® at Histiocyte Society 2026 in Rotterdam
STOCKHOLM, Sept. 24, 2026 // -- Sobi® (STO: SOBI) today announced that new clinical data on Gamifant® (emapalumab) in primary haemophagocytic lymphohistiocytosis (HLH) will be presented at the 2026 Annual Meeting of the
NEWS | Sep 24, 2026, 08:54 AM UTC
M
Sobi and Innate partnership becomes effective after closing conditions
Sobi and Innate Pharma said their previously announced strategic partnership is now effective following completion of closing conditions.
MNA | Sep 17, 2026, 03:30 AM UTC
M
Innate and Sobi partnership becomes effective after closing conditions
Innate Pharma said its previously announced strategic partnership with Sobi is now effective after applicable antitrust waiting periods expired and other closing conditions were completed.
MNA | Sep 16, 2026, 08:00 PM UTC
H
SOBI: Upgraded guidance and robust launches drive growth, with pipeline and partnerships fueling future gains
Strong financial growth and upgraded guidance were driven by successful product launches and pipeline progress. Key franchises like Altuvoct, Aspaveli, and Gamifant are expanding, while new opportunities in gout and lipi
NEWS | Sep 14, 2026, 10:19 PM UTC
H
SOBI: Upgraded guidance and robust launches set the stage for continued growth and portfolio expansion
Strong financial growth and upgraded guidance were driven by successful product launches and portfolio expansion. Key assets like ALTUVOCT, Aspaveli, and Gamifant are fueling growth, while new indications and strategic p
NEWS | Sep 14, 2026, 09:48 PM UTC
M
Sobi gets US FDA Fast Track for pacritinib in VEXAS
Sobi North America said the US FDA granted Fast Track designation to pacritinib for treatment of VEXAS syndrome.
REGULATION | Sep 09, 2026, 05:51 PM UTC